SUPPLEMENTAL WORK-SARS-COV-2
SUPPLEMENTAL WORK-SARS-COV-2
补充工作-SARS-COV-2
批准号：
10260005
负责人：
MICHAEL KAYTOR
金额：
$264.1万
依托单位：
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
项目状态：
已结题
起止时间：
2020-04-01 至 2021-03-31
关键词：
2019-nCoVAntioxidantsCOVID-19Cancer PatientChestClinicDiagnostic radiologic examinationGenisteinHospitalsImpairmentInjuryMalignant neoplasm of lungMediatingMedical centerOralPatientsPulmonary FibrosisPulmonary InflammationQuality of lifeRadiationRadiation therapyWorkefficacy testinglung injurynanoformulationphase II trialpulmonary function
中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The company will initiate a phase 2 trial to evaluate BIO 300 (oral, genistein antioxidant) to mitigate impaired pulmonary function in COVID-19 patients recently discharged from the hospital. COVID-19- and radiation-mediated lung damage share overlapping mechanisms of injury, and Humanetics already has BIO300 under study in the clinic to treat pneumonitis and pulmonary fibrosis in lung cancer patients receiving thoracic radiotherapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SUPPLEMENTAL WORK-SARS-COV-2
-
批准号：10397497
-
项目类别：
-
资助金额：$187.27万
-
财政年份：2019
-
负责人：MICHAEL KAYTOR
-
依托单位：
EXERCISE PHASE II TITLE: DEVELOPMENT OF BIO 300 AS A RADIATION MODULATOR FOR USE DURING RADIOTHERAPY OF LUNG CANCER ; PERIOD OF PERFORMANCE FROM 09/20/2012 TO 01/09/2016DUNS: 197085517CAN8478361
-
批准号：8948720
-
项目类别：
-
资助金额：$149.92万
-
财政年份：2012
-
负责人：MICHAEL KAYTOR
-
依托单位：
海外基金
